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1. ABSTRACT 
 
Loss of heterozygosity (LOH) of tumor suppressor genes is a frequent event in tumorigenesis. 
LOH is most often analyzed by microsatellite typing, but here we offer a fast and efficient 
method for simultaneous SNP genotyping and mutation scanning, which can also be used for 
LOH detection. High resoultion melting (HRM) provides simple variant detection, and can be 
adopted for a wide range of applications. When a melting profile for a specific SNP is 
determined, the screening can be done without the need for sequencing, and only the 
melting profiles differing from the established melting profiles should be sequenced or 
analyzed by other methods. LOH of PTCH1 gene is often found in a series of different 
tumors, for example basal cell carcinoma (BCC) and ovarian carcinoma (OC). In this study 
LOH was detected in 50% of BCC and 27.27% of OC, and the detection rates of microsatellite 
typing and HRM were comparable. Both methods depended only on the heterozygosity of 
the loci analyzed, but HRM offers an additional advantage of detection of all sequence 
variants in the gene of interest. 
 
2. INTRODUCTION 
 
Loss of heterozygosity (LOH) is a change from a state of heterozygosity in a normal genome 
to a homozygous state in a paired tumor genome. LOH is a sign of somatic deletion and is 
most often regarded as a mechanism for disabling tumor suppressor genes during the course 
of oncogenesis (1). Tumor suppressor genes are generally inactivated by an intragenic 
mutation within one allele and the subsequent loss of the corresponding (wild type) allele 
(2).  
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Identification of deleted regions usually relies on genotyping tumor and counterpart normal 
DNA with polymorphic DNA markers, such as microsatellites. Microsatellites are short, 
polymorphic, tandem repeat segments dispersed throughout the human genome. Most 
procedures to detect LOH are based on comparing alleles in tumor and normal tissue after 
PCR amplification with fluorescently labeled fragments, followed by capillary electrophoresis 
on an automated DNA sequencer (3).  
High resolution melting (HRM) analysis is a simple, powerful and robust method for 
detecting DNA sequence variants. The method is based on differences in melting curves 
caused by variations in nucleotide sequence, detected as the change in fluorescence during 
the heating (melting) of the PCR product in the presence of the intercalating dye. The 
advantages of high resolution melting analysis for variant scanning include rapid turn-around 
times, a closed-system environment that greatly reduces contamination risk and, unlike 
other methods, no sample processing or separation after PCR. The method is an ideal choice 
for scanning of novel variants or genotyping known ones. (4).  
Patched (PTCH1) gene is a tumor suppressor gene associated with development of 
basocellular carcinomas (BCC) of the skin. It is a member of the Hedgehog-Gli signaling 
pathway, a pathway that plays a major role in embryonic development and stem cell 
maintenance. The pathway is activated by binding of Hedgehog (Hh) protein to its 
transmembrane receptor Patched (Ptch). Ptch is then internalized, and releases its inhibition 
of Smoothened (Smo) protein, which is transported to the cell surface (reviewed in 5). A 
phosphorylation cascade is then triggered in the cytoplasm, leading to activation of 
transcription factor Gli, which translocates to the nucleus and triggers transcription of target 
genes: Cyclin D2, Cyclin E (6), members of the Wnt signaling pathway (7, 8), N-MYC (9), 
PTCH1 (10), Ceruloplasmin, ITIH3 (11), bcl-2 (12), FOXM1 (13).  
PTCH1 gene is located on chromosome 9, in the chromosome region 9q22.32, with 24 exons 
streching through 70 kb (14). PTCH1 gene has one polymorphic CGG repeat marker located 
directly upstream of the first ATG codon of exon 1b (rs71366293) (15), and at least 48 single 
nucleotide polymorphisms (SNP) throughout the gene (16), 7 of them common (17). 
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Germline mutations of the PTCH1 gene lead to Gorlin syndrome, a syndrome characterized 
with various developmental malformations and tumors (18, 19, 10). Tumor suppressor role 
of the gene causing the Gorlin syndrome was known even before it was cloned in 1996 (20). 
Even then LOH analysis was based on microsatellite markers throughout the whole 9q22.31-
9q22.33 region. Sporadic mutations of the PTCH1 gene are involved in a series of sporadic 
tumors, including BCC (21, 22), medulloblastomas (23), skin trichoepitheliomas (24), 
esophageal squamous cell carcinomas (25), squamous cell carcinomas (26), breast cancer 
(23), as well as in odontogenic keratocysts (27).  
According to the recent research, Hh-Gli signaling pathway is involved in one third of all 
malignant tumors, so it is becoming an interesting target for new cancer therapies (28). The 
role of Hh-Gli signaling pathway in ovarian carcinoma (OC) has been discovered only 
recently. Unlike healthy epithelial ovarian tissue, OC shows increased protein expression of 
the members of the pathway (29). Also, ovarian tumors often show LOH of the PTCH1 gene 
(30). Benign tumors of the ovary also show promoter hypermethylation (31), while OC do 
not (32). 
We aim to provide evidence that the high resolution melting analysis is a simple, fast, 
accurate and inexpensive method to detect LOH, comparable to microsatellite analysis in 
both sensitivity and specificity. 
 
3. MATERIALS AND METHODS 
 
3.1. Patient samples and DNA extraction 
Tumor tissue samples and blood samples from BCC patients were collected at Department of 
Maxillofacial Surgery, Clinical Hospital Osijek, in Osijek, Croatia. Tumor tissue samples and 
blood samples from OC patients were collected at Department of Obstetrics and 
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Gynecology, Zagreb University School of Medicine, in Zagreb, Croatia. All samples were 
collected with patients’ consent according to Declaration of Helsinki, and ethical committees 
of both institutions approved the study. In total 25 BCC samples from 19 patients and 12 OC 
samples from 12 patients were collected. DNA was extracted from tissues using the standard 
phenol-chloroform method, and from blood using the desalting method. 
3.2. Microsatellite analysis of LOH 
LOH analysis was done using fluorescent labeled forward primers, followed by fragmental 
analysis detection on ABI PRISM 310 Genetic Analyzer (Applied Biosystems, USA).  
DNA of 25 BCC and 12 OC samples were typed for CGG repeat in 5’UTR of PTCH1 gene 
(rs71366293) using following primers: F: 5' CCCCCGCGCAATGTGGCAATGGAA '3 and R: 5' 
CGTTACCAGCCGAGGCCATGTT '3 (33). Samples that were uninformative were further typed 
for three additional STR markers (D9S196, D9S287 and D9S180) (17). 
PCR conditions for CGG repeat were: initial denaturation at 95°C for 10 min, followed by 30 
cycles of 95°C 30s, 61°C 2 min, 72°C 1 min, and final extension at 72°C 30 min using AmpliTaq 
Gold polymerase (Applied Biosystems, USA). 
PCR conditions for the multiplex PCR with other STR markers: initial denaturation at 95°C for 
15 min, followed by 19 cycles of 95°C 30 s, 55°C 90s, 72°C 1min, and final extension at 72°C 
30 min using QIAGEN Multiplex PCR kit (QIAGEN, Germany). 
3.3. High resolution melting analysis of SNPs 
PCR reactions were performed in a 10 µl reaction mixture in Roche LightCycler capillaries 
using the following components: 50 ng template DNA, 0.2 mM dNTPs (Roche, Mannheim, 
Germany), 0.4 U FastStart Taq DNA Polymerase (Roche), 1x fluorescent dye LCGreen Plus 
(Idaho Technology, Salt Lake City, ID, USA), 2 mM MgCl2 (Idaho Technology) and forward 
and reverse primers (0.5 mM each) for each gene segment. PCR reaction was performed in 
an adapted RapidCycler2 instrument (Idaho Technology). Coding region of the PTCH1 gene 
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was split into 24 PCR products, sized between 168 and 428 bp. PCR conditions were 
optimized to temperatures between 52oC and 64oC for each segment. After 40 cycles of 
amplification, PCR products underwent an additional 1 min at 98oC and then 5 min at 40oC to 
promote heteroduplex formation. Each capillary was then transferred to the High Resolution 
Melter instrument (HR-1, Idaho Technology) for high resolution melting and curve analysis. 
Samples were melted at 0.2oC/s ramp rate (34). Melting profiles were analyzed with HR-1 
software using fluorescence normalization, temperature shift and conversion to difference 
and derivative plots. Paired blood and tissue samples were compared, and samples showing 
a difference in melting profiles were sequenced. 
3.4. DNA sequencing 
Before sequencing, the chosen PCR products were purified with ExoSAP-IT (USB, Cleveland, 
OH, USA) and then sequenced in both directions using the Big Dye Terminator 1.1 Cycle 
Sequencing kit (Applied Biosystems, Foster City, CA, USA). Sequencing reaction was 
performed on an automatic sequencer ABI PRISM 310 Genetic Analyzer (Applied 
Biosystems), and sequences were analyzed using BioEdit program.  
3.5. Statistical analysis 
Kappa statistics κ (35) were used for evaluating inter-rater agreement between two LOH 
analysis methods and κ values were interpreted according to Landis and Koch (36). Fisher’s 
exact test was used for assessing difference in LOH distribution between BCC and OC 
samples (two-tailed P value < 0.05 was considered statistically significant). Statistical 
analyses were performed with MedCalc for Windows, version 11.4.2.0 (MedCalc Software, 
Mariakerke, Belgium). 
 
4. RESULTS 
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4.1. Microsatellite analysis 
LOH of the PTCH1 region was determined in 10 of 25 BCC from 9 patients (40%) (Figure 1, 
Table 1-left part). Twelve BCC samples from 11 patients had no LOH, while 3 samples from 2 
patients were uninformative for all 4 markers used (D9S196, rs71366293, D9S287 and 
D9S180). So the prevalence of LOH in BCC was 45.45% (10/22). 
Six patients had two BCCs analyzed. Of those, three had LOH in one tumor but not in the 
other, one had LOH in both tumors, one had no LOH, and one was uninformative for all 
markers. 
In OC samples, LOH of the PTCH1 region was determined in 3 of 12 cases (25%) (Table 1-left 
part). Seven OC samples had no LOH, and 2 samples were uninformative for all markers 
analyzed. The prevalence of LOH in OC was 30% (3/10). 
4.2. HRM analysis 
Using the HRM analysis and sequencing, LOH was detected in BCC samples with SNPs 
located in exons 5 (c.735A>G), 12 (c.1665T>C, c.1686C>T), 14 (c.2199A>G) and 23 
(c.3944C>T), and introns 1 (c.202-539delC), 5 (c.747-55T>C), 10 (c.1504-51C>G) and 15 
(c.2560+9G>C) (Figure 2, Figure 3, Table 1-right part). 
We considered 1 informative SNP enough evidence for confirmation of LOH, and in all 
samples analyzed all SNPs corresponded together, that is, when more than one SNP was 
informative they all either showed LOH or did not. LOH was detected in 10 BCC samples, 
with 1 up to 4 SNPs being informative.  
Eleven samples showed no LOH, with 1 to 4 SNPs being informative. Four samples were 
homozygotic for all PTCH1 exons analyzed, so no information about LOH could be gathered. 
The prevalence of LOH in BCCs detected by HRM was 47.6% (10/21) 
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In ovarian carcinoma samples LOH was found in exons 12 (c.1686CT) and 23 (c.3944C>T), 
and introns 1(c.202-539delC), 5 (c.747-55T>C) and 15 (c.2560+9G>C). LOH was found in 3 
samples, with 4 or 5 SNPs being informative (Table 1-right part). 
LOH was not found in 7 samples, with 2 up to 6 SNPs being informative. Two samples were 
homozygotic for all PTCH1 exons analyzed, so no information about LOH could be gathered. 
In ovarian carcinomas, the prevalence of LOH detected by HRM was 30% (3/10) 
4.3. Comparison of two methods 
The inter-rater agreement between microsatellite and HRM LOH analyses obtained a κ value 
of 0.821, what can be interpreted as very good agreement (Table 2-upper half). When we 
excluded samples that were uninformative by either method, the κ value was even higher: 
0.932 (Table 2-lower half). For BCC samples, data from microsatellite and HRM analysis 
corresponded in nine samples that showed LOH, 11 samples that did not show LOH and 
three samples that were uninformative. The results did not match in two cases: in one case 
(BCC18) microsatellite analysis showed LOH, while the HRM analysis was uninformative. In 
this case the microsatellite analysis showed itself to be more accurate. In the second case 
(BCC21), the microsatellite analysis showed no LOH, while the HRM analysis showed LOH in 
4 SNPs. Here the HRM analysis was more accurate. 
For OC samples, data from two analyses corresponded in three samples that showed LOH, 6 
samples that showed no LOH, and one uninformative sample. The data did not match in two 
cases. In one case (OC5) the microsatellite analysis showed no LOH, while the SNPs were 
uninformative, and in the second (OC10), the microsatellite were uninformative; while the 
SNPs showed that there was no LOH. 
Combining the results from both methods, the prevalence of LOH in BCCs was 50.0% (11/22) 
while in OC samples was 27.27% (3/11). There was no statistically significant difference 
between the prevalence in BCCs and OC (P=0.278, Figure 4). 
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5. DISCUSSION 
 
High resolution melting analysis has mostly been used for mutation scanning or genotyping 
(detection of SNPs) in a variety of different systems (reviewed in 37). So far only one paper 
mentions the possibility of LOH detection using melting curve analysis (38), although a 
similar concept was established previously using denaturing high-performance liquid 
chromatography (DHPLC) (39). LOH has previously mostly been detected by microsatellite 
typing (3). More recently, oligonucleotide SNP arrays have become another tool for LOH 
detection although it is limited by availability (1). HRM has become widely available in a 
variety of applications, which has been demonstrated by the number of publications in the 
recent years (reviewed in 4).  
In our research we compared the HRM approach with the classic microsatellite analysis. We 
determined that LOH can be easily detected using HRM when comparing melting curves 
from blood and tissue samples, on SNP locations. In these cases there is a visible difference 
in melting curve profiles between tumor and blood sample from the same patient. Usually 
the difference is a clear shift of the melting profile from a heterozygous towards wild type or 
homozygous form, indicating complete or partial loss of one of the alleles. When a melting 
profile for a specific SNP is determined, the screening can be done without the need for 
sequencing, and only the melting profiles differing from the established melting profiles 
should be sequenced or analyzed by other methods.  
The detection rate between HRM and microsatellite analysis was comparable, and both 
were dependant on the heterozygosity of the used loci. The prevalence of LOH was 50% for 
BCC, and 27.27% for OC. In literature the prevalence of LOH in BCCs is between 35 and 75% 
(40, 22, 41, 42, 26) and 70% for ovarian tumors, both benign and malignant (30). Our data is 
comparable with published data for BCC, but is significantly lower for OC. That is probably 
because of the small number of our OC samples, but we are confident in our results, because 
of high agreement of both methods used.  
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When we compared the HRM and microsatellite analysis, our data corresponded in most 
samples. The data differed in four samples, two BCCs and two OC. In one sample (BCC18), 
microsatellite analysis showed LOH, while it was uninformative for the SNPs. While we can 
predict that this means the sample has the LOH in the PTCH1 gene, since the microsatellite 
marker (D9S180) is almost 2 Mb away, we cannot say anything for certain. In the second BCC 
case, where the microsatellite analysis showed no LOH, while the HRM analysis showed LOH, 
we can be 100% confident that there is a LOH in the PTCH1 gene. In one OC case, where the 
microsatellite analysis showed no LOH and the SNPs were uninformative, we cannot say for 
sure if there really was no LOH (again because of the 2 Mb distance of D9S180). For the 
second OC case, the microsatellites were uninformative, while the SNPs confirmed that 
there was no LOH. So, while in two cases the microsatellites were more informative, due to 
the distance of markers used, it cannot be certain that the PTCH1 gene itself was lost. In the 
second two cases, where the SNPs were more informative, the data is more certain, because 
the SNPs are located in the gene itself.  
The only limitation of the HRM method (as well as the microsatellite, or SNP microarray) is 
the need for SNPs. There are some methods for LOH detection that do not need SNPs, such 
as Multiplex ligation-dependent probe amplification (MLPA) (43), comparative genomic 
hybridization (CGH) (44), or whole genome sequencing but they are still not widely used. 
For researchers interested in complete genetic analysis of a gene, we recommend HRM as 
the method of choice, due to its ability to perform scanning for point mutations and LOH 
analysis in the same reaction. Here we show it with the PTCH1 gene, but the method could 
be equally applied to any gene containing common SNPs. 
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7. FIGURE LEGENDS 
 
Figure 1. Microsatellite analysis for marker rs71366293 showing two typical LOH results 
compared to control sample. LOH is calculated from peak height ratio using the following 
formula: LOH<0.66<normal<1.5<LOH. 
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Figure 2. HRM analysis of c.202-539delC (A), c.747-55T>C (B), c.1686C>T (C) and 
c.2560+9G>C (D) in the PTCH1 gene. Two different modes of analysis are shown - difference 
or derivative plots. Normal samples are shown in black, samples homozygous for minor 
allele in grey, while samples showing LOH are shown in matched color. DNA from blood is 
shown in dashed lines and DNA from tumor tissue in full lines. LOH samples clearly differ 
from heterozygous curves. The curves show: partial loss of one allele (A), complete loss of 
one allele (B) and both partial and complete loss of one allele (C) and (D).  
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Figure 3. DNA sequencing result showing LOH for c.1686C>T. Upper sequence is 
heterozygous, while lower shows the loss of one allele (arrow). 
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Figure 4. The prevalence of PTCH1 LOH in BCC and OC. Lighter bars represent samples 
without LOH, darker bars represent samples with LOH. No statistically significant difference 
was observed between BCC and OC (P value for Fisher's exact test was 0.278). 
 
 
Musani V1, Sabol M, Car D, Ozretic P, Oreskovic S, Leovic D, Levanat S. LOH of PTCH1 region in BCC 
and ovarian carcinoma: microsatellite vs. HRM analysis. Front Biosci (Elite Ed). 2012 Jan 1;4:1049-57. 
DOI: 10.2741/440 (postprint version) 
 
8. TABLES 
Article in press - uncorrected proof 
Musani V1, Sabol M, Car D, Ozretic P, Oreskovic S, Leovic D, Levanat S. LOH of PTCH1 region in BCC 
and ovarian carcinoma: microsatellite vs. HRM analysis. Front Biosci (Elite Ed). 2012 Jan 1;4:1049-57. 
DOI: 10.2741/440 (postprint version) 
 
Table 1 – LOH status of BCC (BCC1-BCC25) and OC (OC1-OC12) samples for four 
microsatellite loci in PTCH1 gene region and 7 common SNPs detected with HRM in PTCH1 
gene. N – normal, HET – heterozygous, HO – homozygous for minor allele, LOH – loss of 
heterozygosity, UI – uninformative, ND – not done, - - PCR amplification unsuccessful. No 
lines between samples – two samples from the same patient. 
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BCC1 HET HO HO HET no LOH N N HET N N N HET no LOH 
BCC2 HO HO HO HO UI N N HO N N N HO UI 
BCC3 LOH HO HO LOH LOH N HO N N HO N LOH LOH 
BCC4 HET HO HO HET no LOH N HO N N HO N HET no LOH 
BCC5 HET HO HET HO no LOH N HET N N HET HET N no LOH 
BCC6 LOH HO HO LOH LOH N N LOH N N N LOH LOH 
BCC7 HET HO HO LOH LOH N N LOH N N N LOH LOH 
BCC8 HO LOH LOH LOH LOH N N N LOH N LOH LOH LOH 
BCC9 HO HO HO HET no LOH N N HET N N N HET no LOH 
BCC10 HET HO HET HO no LOH N N HET N N N N no LOH 
BCC11 HET HO HET HO no LOH N N HET N N N N no LOH 
BCC12 HET HO HET HO no LOH N N N N N N HET no LOH 
BCC13 HO HO HO HO UI N N HO N N N HO UI 
BCC14 HO HO HO HO UI N N HO N N N HO UI 
BCC15 LOH HO HO LOH LOH N N LOH N N N LOH LOH 
BCC16 HO HO HO LOH LOH N N LOH N N N N LOH 
BCC17 HO HO HO HET no LOH N N HET N N N N no LOH 
BCC18 HO HO HO LOH LOH N N - N N N N UI 
BCC19 HO HO HO HET no LOH N N HET HET N HET HET no LOH 
BCC20 HO LOH LOH LOH LOH LOH LOH N N LOH LOH N LOH 
BCC21 HO HO HO HET no LOH N N LOH LOH N LOH LOH LOH 
BCC22 HO HO HET HET no LOH N N HET N N HET N no LOH 
BCC23 ND LOH ND ND LOH N N LOH N N LOH N LOH 
BCC24 ND LOH ND ND LOH N LOH LOH N LOH LOH LOH LOH 
BCC25 ND HET ND ND no LOH N HET HET N HET HET HET no LOH 
OC1 - LOH LOH LOH LOH LOH LOH N N LOH LOH LOH LOH 
OC2 HET HET HET HO no LOH HET N HET N HET HET HET no LOH 
OC3 HO HO HET HO no LOH HO N HET N HET HET N no LOH 
OC4 HO HET HET HO no LOH HET N HET N HET HET HET no LOH 
OC5 HO HO HO HET no LOH N N N N N N N UI 
OC6 - HO - - UI N HO N N HO HO N UI 
OC7 HO LOH ND ND LOH LOH LOH HO N LOH LOH N LOH 
OC8 ND HET ND ND no LOH HET N HET N N HET N no LOH 
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OC9 ND HET ND ND no LOH HET N N HET HET HO N no LOH 
OC10 HO HO HO HO UI N N N N HET HET N no LOH 
OC11 ND LOH ND ND LOH LOH LOH N N LOH LOH N LOH 
OC12 ND HET ND ND no LOH HET HET HET N HET HET HET no LOH 
Table 2 – Inter-rater agreement between microsatellite and HRM analyses. Upper half of the 
table – all samples. Lower half – samples informative for both methods. 
 Microsatellite Analysis   
 uninformative no LOH LOH Total 
High 
resolution 
Melting 
Analysis 
uninformative 
4 1 1 6 (16.2%) 
no LOH 
1 17 0 18 (48.6%) 
LOH 
0 1 12 13 (35.1%) 
Total 5 (13.5%) 
19 
(51.4%) 13 (35.1%) 37 
    
Kappa 
0.821  
     
 Microsatellite Analysis    
 no LOH LOH Total  
High 
resolution 
Melting 
Analysis 
no LOH 
17 0 17 (56.7%)  
LOH 
1 12 13 (43.3%)  
Total 18 (60 %) 
12 
(40%) 30  
   
Kappa 
0.932  
     
 
